Life Science Nation Newsletter  |  November 25, 2015  |  Issue 139

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Nov 19 - Nov. 24)
Seeks PMA & 510k Medical Devices
Interested in Dental, Aesthetics and Mobile Tech
Invests in Technology Platforms in Medtech & Lab Equipment
Invests in Diagnostics, HCIT, Devices & Enabling Technologies
Invests in Medtech & HCIT Hospital Solutions in NoCal
Invests in Cancer Cures Worldwide
Invests in Pharmaceuticals & Medtech in the USA
Seeks Healthcare Opportunities in India
Invests in HCIT, Medical Devices and Diagnostics in Europe
Seeks Strategic Medtech Opportunities for China Expansion
In This Issue
LSN Videos
RESI Boston 2015 Investors Panel

Video Recap of [email protected] 2015

LSN Wishes You A Happy Thanksgiving And A Fruitful Fundraising Campaign
By Dennis Ford, Founder & CEO, LSN

This Thanksgiving, we'd like to say thank you for all our Next Phase readers, LSN platform subscribers, RESI attendees and all our friends in the life science investment and entrepreneurship communities. We're grateful for your support, and we hope to support your success in turn during the year to come.

As is LSN's Thanksgiving tradition, we're serving up the 10 most recent life science investment mandates gathered by LSN Research. These mandates show the breadth of coverage that LSN has among life science investors, with investors including international PE firms, expert regional VCs, disease-focused nonprofits, cross-border funds, and family offices. If one of these investors is a fit for your opportunity, we'd love to hear from you...

     READ MORE  
RESI SF Panel Annoucement: Big Pharma
By Lucy Parkinson, Director of Research, LSN

One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.

At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company's evaluation process, and what can you do to position your startup to make a deal?  Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.

Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:
  • Habib Dable, President of US Pharmaceuticals, Bayer Healthcare Pharmaceuticals
  • Jason Coloma, Vice President, Global Head Roche Partnering Oncology, Roche
  • Lesley Stolz, Senior Director of Transactions, Johnson & Johnson Innovation
  • Tomas Landh, Vice President, Strategy and Innovation Sourcing, Novo Nordisk